Portside Wealth Group LLC bought a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 564 shares of the company's stock, valued at approximately $237,000.
Several other hedge funds also recently modified their holdings of the company. United Capital Financial Advisors LLC boosted its position in IDEXX Laboratories by 0.9% in the 4th quarter. United Capital Financial Advisors LLC now owns 2,446 shares of the company's stock valued at $1,011,000 after buying an additional 22 shares during the last quarter. Gabelli Funds LLC grew its stake in IDEXX Laboratories by 5.3% during the 4th quarter. Gabelli Funds LLC now owns 500 shares of the company's stock valued at $207,000 after purchasing an additional 25 shares in the last quarter. Summit Trail Advisors LLC increased its holdings in IDEXX Laboratories by 3.3% during the 4th quarter. Summit Trail Advisors LLC now owns 810 shares of the company's stock worth $335,000 after purchasing an additional 26 shares during the last quarter. Forum Financial Management LP raised its position in shares of IDEXX Laboratories by 4.9% in the 4th quarter. Forum Financial Management LP now owns 621 shares of the company's stock valued at $257,000 after purchasing an additional 29 shares in the last quarter. Finally, Retirement Wealth Solutions LLC boosted its stake in shares of IDEXX Laboratories by 40.0% during the 1st quarter. Retirement Wealth Solutions LLC now owns 105 shares of the company's stock valued at $44,000 after buying an additional 30 shares during the last quarter. 87.84% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several analysts recently issued reports on the stock. Wall Street Zen cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a report on Friday, May 30th. Stifel Nicolaus increased their price target on shares of IDEXX Laboratories from $460.00 to $510.00 and gave the stock a "hold" rating in a research report on Monday, May 19th. Morgan Stanley boosted their price objective on IDEXX Laboratories from $548.00 to $558.00 and gave the company an "overweight" rating in a report on Monday, May 5th. Finally, Leerink Partners lifted their target price on IDEXX Laboratories from $515.00 to $580.00 and gave the stock an "outperform" rating in a research report on Wednesday. Four analysts have rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $546.00.
View Our Latest Stock Analysis on IDEXX Laboratories
Insider Activity
In other news, Director M Anne Szostak sold 1,046 shares of IDEXX Laboratories stock in a transaction that occurred on Wednesday, May 21st. The shares were sold at an average price of $513.74, for a total value of $537,372.04. Following the transaction, the director now owns 262 shares of the company's stock, valued at $134,599.88. The trade was a 79.97% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.98% of the company's stock.
IDEXX Laboratories Stock Performance
IDXX stock traded up $2.74 during mid-day trading on Thursday, reaching $526.92. The company had a trading volume of 379,293 shares, compared to its average volume of 649,762. IDEXX Laboratories, Inc. has a one year low of $356.14 and a one year high of $530.73. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock has a market capitalization of $42.38 billion, a P/E ratio of 49.38, a P/E/G ratio of 3.41 and a beta of 1.55. The stock's 50-day simple moving average is $466.92 and its two-hundred day simple moving average is $442.89.
IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The company reported $2.96 EPS for the quarter, beating analysts' consensus estimates of $2.93 by $0.03. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The company had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. During the same period last year, the company earned $2.71 earnings per share. The company's quarterly revenue was up 3.6% compared to the same quarter last year. Research analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.
About IDEXX Laboratories
(
Free Report)
IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.
Read More
Before you consider IDEXX Laboratories, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IDEXX Laboratories wasn't on the list.
While IDEXX Laboratories currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
